Cargando…

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis par...

Descripción completa

Detalles Bibliográficos
Autores principales: Susai, Subash Raj, Healy, Colm, Mongan, David, Heurich, Meike, Byrne, Jonah F., Cannon, Mary, Cagney, Gerard, Wynne, Kieran, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y. H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Yung, Alison Ruth, Nelson, Barnaby, McGorry, Patrick D., Föcking, Melanie, Amminger, G. Paul, Cotter, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616837/
https://www.ncbi.nlm.nih.gov/pubmed/36307392
http://dx.doi.org/10.1038/s41398-022-02217-0
_version_ 1784820727720968192
author Susai, Subash Raj
Healy, Colm
Mongan, David
Heurich, Meike
Byrne, Jonah F.
Cannon, Mary
Cagney, Gerard
Wynne, Kieran
Markulev, Connie
Schäfer, Miriam R.
Berger, Maximus
Mossaheb, Nilufar
Schlögelhofer, Monika
Smesny, Stefan
Hickie, Ian B.
Berger, Gregor E.
Chen, Eric Y. H.
de Haan, Lieuwe
Nieman, Dorien H.
Nordentoft, Merete
Riecher-Rössler, Anita
Verma, Swapna
Street, Rebekah
Thompson, Andrew
Yung, Alison Ruth
Nelson, Barnaby
McGorry, Patrick D.
Föcking, Melanie
Amminger, G. Paul
Cotter, David
author_facet Susai, Subash Raj
Healy, Colm
Mongan, David
Heurich, Meike
Byrne, Jonah F.
Cannon, Mary
Cagney, Gerard
Wynne, Kieran
Markulev, Connie
Schäfer, Miriam R.
Berger, Maximus
Mossaheb, Nilufar
Schlögelhofer, Monika
Smesny, Stefan
Hickie, Ian B.
Berger, Gregor E.
Chen, Eric Y. H.
de Haan, Lieuwe
Nieman, Dorien H.
Nordentoft, Merete
Riecher-Rössler, Anita
Verma, Swapna
Street, Rebekah
Thompson, Andrew
Yung, Alison Ruth
Nelson, Barnaby
McGorry, Patrick D.
Föcking, Melanie
Amminger, G. Paul
Cotter, David
author_sort Susai, Subash Raj
collection PubMed
description Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins.
format Online
Article
Text
id pubmed-9616837
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96168372022-10-30 Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis Susai, Subash Raj Healy, Colm Mongan, David Heurich, Meike Byrne, Jonah F. Cannon, Mary Cagney, Gerard Wynne, Kieran Markulev, Connie Schäfer, Miriam R. Berger, Maximus Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Street, Rebekah Thompson, Andrew Yung, Alison Ruth Nelson, Barnaby McGorry, Patrick D. Föcking, Melanie Amminger, G. Paul Cotter, David Transl Psychiatry Article Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins. Nature Publishing Group UK 2022-10-28 /pmc/articles/PMC9616837/ /pubmed/36307392 http://dx.doi.org/10.1038/s41398-022-02217-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Susai, Subash Raj
Healy, Colm
Mongan, David
Heurich, Meike
Byrne, Jonah F.
Cannon, Mary
Cagney, Gerard
Wynne, Kieran
Markulev, Connie
Schäfer, Miriam R.
Berger, Maximus
Mossaheb, Nilufar
Schlögelhofer, Monika
Smesny, Stefan
Hickie, Ian B.
Berger, Gregor E.
Chen, Eric Y. H.
de Haan, Lieuwe
Nieman, Dorien H.
Nordentoft, Merete
Riecher-Rössler, Anita
Verma, Swapna
Street, Rebekah
Thompson, Andrew
Yung, Alison Ruth
Nelson, Barnaby
McGorry, Patrick D.
Föcking, Melanie
Amminger, G. Paul
Cotter, David
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title_full Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title_fullStr Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title_full_unstemmed Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title_short Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
title_sort evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: a mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616837/
https://www.ncbi.nlm.nih.gov/pubmed/36307392
http://dx.doi.org/10.1038/s41398-022-02217-0
work_keys_str_mv AT susaisubashraj evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT healycolm evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT mongandavid evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT heurichmeike evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT byrnejonahf evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT cannonmary evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT cagneygerard evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT wynnekieran evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT markulevconnie evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT schafermiriamr evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT bergermaximus evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT mossahebnilufar evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT schlogelhofermonika evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT smesnystefan evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT hickieianb evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT bergergregore evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT chenericyh evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT dehaanlieuwe evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT niemandorienh evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT nordentoftmerete evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT riecherrossleranita evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT vermaswapna evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT streetrebekah evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT thompsonandrew evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT yungalisonruth evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT nelsonbarnaby evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT mcgorrypatrickd evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT fockingmelanie evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT ammingergpaul evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis
AT cotterdavid evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis